Silent in the bloodstream.
Active in the tumor.
Drug release is triggered ONLY at the tumor site by FAP, a protein found in tumor-supporting cells.
Our scientific approach leverages existing cancer drugs that are delivered precisely to the tumor using our proprietary technology.
Our innovative technology links a peptide to an existing cancer drug to inactivate it. The peptide can only be removed by an enzyme found in the tumor (FAP).
Our pre|CISION technology is designed to concentrate the active drug in the tumor while maintaining the inactive pre|CISION-enabled drug in the bloodstream.
The future of cancer treatment means not having to choose between eliminating cancer cells and safeguarding patient wellness.
To conquer cancer with existing therapies while preserving patient vitality and healing.
